|Bid||13.00 x 1000|
|Ask||15.50 x 800|
|Day's Range||14.80 - 15.00|
|52 Week Range||12.00 - 18.75|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||25.33|
SOUTH SAN FRANCISCO, Calif., April 08, 2019 -- NGM Biopharmaceuticals, Inc. (Nasdaq: NGM), a clinical stage biotechnology company focused on harnessing powerful biology to.
Another unicorn is lining up an IPO for later this year and 10 Bay Area companies raised about $175 million in funding at week's end. Here are the details.
NGM Biopharmaceuticals, Inc. (“NGM”) today announced the pricing of its initial public offering of 6,666,667 shares of common stock at a price to the public of $16.00 per share. In addition, NGM has granted the underwriters a 30-day option to purchase up to 1,000,000 additional shares of common stock at the initial public offering price less underwriting discounts and commissions. The shares are expected to begin trading on The Nasdaq Global Select Market under the symbol “NGM” on April 4, 2019, and the offering is expected to close on April 8, 2019, subject to customary closing conditions.
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Ruhnn Holding Ltd (RUHN) will issue 10 million shares between $11.50 ...
TPI Composites (NGM) makes wind blades for wind turbines which it sells to turbine manufacturers; in fact it is the only independent manufacturer of composite wind blades for the high growth wind energy market with a global footprint, explains small cap expert Tom Bishop, editor of BI Research.